Replies to post #223728 on Biotech Values

[Maciste]

MRKR


"I suspect MRKR is going to be one of those early buyout/high premium type of situations, since the technology is impressive"

I agree, but I don't see that happening this year.

[biomaven0]

>MRKR

It's hard to judge these results in a single-arm study - a lot of AML patients do well after a successful transplant. And AML patients are so varied that it makes single arm studies like this harder to interpret. (But I haven't looked at detailed results).